NovoCure : 2022 environmental, social & governance report

2022 NOVOCURE

environmental, social & governance report

table of contents

INTRODUCTION ������������������������������������������������������������������������������������������������	p. 03
ABOUT NOVOCURE	p. 05
PATIENTS	p. 10
EMPLOYEES	p. 15
COMMUNITIES & ENVIRONMENT ��������������������������������������������������������������	p. 23
CORPORATE GOVERNANCE & COMPLIANCE ���������������������������������������	p. 28
QUALITY & SAFETY	p. 37
APPENDIX	p. 41

2022 Novocure environmental, social & governance report

2

INTRODUCTION ABOUT NOVOCURE

PATIENTS

EMPLOYEES COMMUNITIES & ENVIRONMENT

CORPORATE GOVERNANCE & COMPLIANCE

QUALITY & SAFETY

APPENDIX

letter from the CEO

Novocure was founded over 20 years ago on the idea that our novel therapy, Tumor Treating Fields (TTFields), could be harnessed to disrupt cancer cell division and extend the survival of patients diagnosed with aggressive cancers.

Since that time, we have treated over 27,000 patients and expanded our global footprint to treat patients in 10 leading

markets. In the coming years, we expect to complete studies that could lead to the use of TTFields therapy in the treatment of numerous solid tumor cancers. The future is bright for Novocure, and we look forward to potentially impacting the lives of many more patients.

From our Device Support Specialists assisting patients throughout their TTFields therapy journeys, to our product development teams exploring potential improvements to our device, every person at Novocure keeps the needs of our patients at heart. Patient wellbeing has been at the forefront of our mission since our founding, and we expect that same patient-forward focus from our team as we anticipate growth in the years to come.

As we near an inflection point for our business, the need to act with integrity and empathy has never been stronger. We are committed to operating honestly, responsibly, and ethically in all of our interactions. We believe our commitment to these principles enables us to be the best possible partner for all of our stakeholders, including our patients, caregivers, employees, families, communities and shareholders. Our commitment to our values will be integral to our future growth as a company, and we look forward to updating you on our progress.

Sincerely,

Asaf Danziger,

Chief Executive Officer

2022 Novocure environmental, social & governance report

3

INTRODUCTION ABOUT NOVOCURE

PATIENTS

EMPLOYEES COMMUNITIES & ENVIRONMENT

CORPORATE GOVERNANCE & COMPLIANCE

QUALITY & SAFETY

APPENDIX

letter from the CFO

At Novocure, our patient-forward mission connects and inspires us.

We are driven by a deep commitment to extend and improve the lives of cancer patients around the world. But we know that achieving this goal requires more than just developing innovative technologies and treatments. It also requires a focus on the broader environmental, social and governance (ESG) issues that shape the world in which we operate.

We take this responsibility seriously, and we constantly look for ways to drive positive change. Novocure's Nominating and Corporate Governance Committee oversees our ESG policies and practices, and I proudly lead the ESG working group, which embeds ESG priorities throughout our organization. Throughout 2022, we took concrete steps to advance our goals.

On the environmental front, we recognize that climate change and other environmental challenges affect the health of our planet and our communities. As stewards of our planet, we must be mindful of the environmental impact our of operations and take actions to reduce the impact wherever possible. Within Novocure, that means reducing carbon emissions associated with business travel, sourcing packaging materials locally when possible and expanding our efforts to re-use or repurpose equipment in accordance with relevant safety standards.

Social issues are also critical considerations in advancing cancer care. Cancer affects people from all walks of life, but the burden is not distributed equally. We must advocate for policies and practices that promote health equity and strive to ensure that all patients have access to the care and support that they need.

2022 Novocure environmental, social & governance report

At the same time, we are committed to ensuring that all of our employees and partners are treated with the dignity and respect they deserve. We believe that diversity, equity and inclusion are essential to our success as a company, and we are working hard to create a culture where everyone feels valued and supported. As a part of Novocure's commitments, we are focused on developing a more diverse talent pool across all levels of the organization and we continue to support multiple work streams initiated by our Inclusion Council, including inclusive mindset and language training and heritage and identity awareness. We recently launched Novocure Women, an initiative to increase exposure, expand peer networking and provide targeted development opportunities intended to support and propel women in their careers at Novocure.

Finally, we recognize that ethical leadership and strong governance are essential to building trust with our stakeholders. We are mindful of the complex regulatory landscapes that govern healthcare delivery around the globe and maintain a steadfast commitment to transparency, accountability and compliance. We feel a great responsibility to our patients, and we are committed to providing high-quality products and ensuring product integrity and patient safety throughout the product lifecycle.

I believe ESG is about recognizing that we are all connected, and that our actions have an impact beyond ourselves. By embracing these principles, we can create sustainable value for all of our stakeholders, including patients and caregivers, employees and their families, and the wider communities in which we operate. I am inspired by the progress our employees made in 2022 and look forward to sharing continued progress in the years to come.

Sincerely,

Ashley Cordova,

Chief Financial Officer

4

INTRODUCTION ABOUT NOVOCURE PATIENTS

EMPLOYEES COMMUNITIES & ENVIRONMENT

CORPORATE GOVERNANCE & COMPLIANCE

QUALITY & SAFETY

APPENDIX

about Novocure

who we are

In 2000, Novocure was founded by Professor Yoram Palti of the Technion - Israel Institute of Technology. He hoped to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Professor Palti's since-proven hypothesis was based on the use of alternating electric fields, which can kill cancer cells when applied at specific frequencies. This breakthrough ultimately led to the development of our innovative therapy, Tumor Treating Fields, or TTFields.

Novocure's patient-forward approach continues to drive our mission today - together with our patients, we strive to extend survival in some of the most aggressive forms of cancer through the development and commercialization of Tumor Treating Fields. We have over 1,300 team members and operations in multiple countries across North America, Europe and Asia. We have treated over 27,000 patients, to date, and TTFields therapy is currently available to treat certain types of cancer in 10 global markets.

2022 Novocure environmental, social & governance report

Yoram Palti, M.D., Ph.D., Founder

5